Form 4: Gyre Therapeutics President Sells Shares Under 10b5-1 Trading Plan

Songjiang Ma, President of Gyre Therapeutics, sold shares of common stock on May 12 and 13, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 12, 2025, Songjiang Ma, President of Gyre Therapeutics, sold 2,000 shares of common stock at a weighted average price of $10.56.
• On May 13, 2025, Mr. Ma sold another 2,000 shares of common stock at a weighted average price of $11.37.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2024.
• Following these transactions, Mr. Ma directly owns no shares, but indirectly owns 2,820,844 shares through his spouse.

Sentiment

Score: 5

Explanation: The document itself is neutral, simply reporting stock sales. The sentiment depends on the broader context of the company's performance and the reasons behind the executive's decision to sell.

Industry Context

Executive stock sales are common and often pre-planned using 10b5-1 trading plans to avoid accusations of insider trading. The market will likely interpret this sale in the context of the company's recent performance and future prospects.

Comparison to Industry Standards

• Executive compensation and stock ownership are closely monitored in the biotech industry.
• Companies like Amgen, Gilead, and Biogen have similar reporting requirements for insider transactions.
• The use of 10b5-1 plans is a standard practice among publicly traded companies to manage insider sales in a transparent manner.

Stakeholder Impact

• Shareholders may react to the news of the stock sale, depending on their perception of the company's prospects and the reasons for the sale.
• The impact on employees is likely minimal unless the sale signals a significant change in the company's direction.

Key Dates

Keywords

Form 4, Gyre Therapeutics, Songjiang Ma, stock sale, 10b5-1 trading plan, insider trading